OctoPlus announces opening of Boston office
09.01.2007 - Leiden, the Netherlands, OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today the official opening of its business development office in Boston.
A large and growing part of OctoPlus’ clients is located in North America. With the office in Boston, OctoPlus aims to better service those clients and further expand its business in North America. The office will be operated by OctoPlus Inc., a wholly owned subsidiary of OctoPlus N.V. The Boston office will support OctoPlus’ drug development activities as well as its drug formulation and manufacturing business.
OctoPlus has appointed Michiel Lodder, Ph.D., as Director Business Development, North-America. Dr. Lodder was previously Manager Business Development and Project Leader at OctoPlus’ headquarters in Leiden, the Netherlands.
“We are very happy that OctoPlus has a presence in North America now,” says Joost Holthuis, CEO of OctoPlus. “We want to continue to expand our business in that region and with a local office, we can better support our clients and maximize the commercial opportunities there.”
For further information about the Boston office, please contact:
Michiel Lodder, Director Business Development, +1 617 225 2510 or e-mail email@example.com .
OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on its proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics and other drugs.
OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that OctoPlus derives from rendering formulation and manufacturing services help to support its own drug development programs.
This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.’s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words “expect”, “anticipate”, “predict”, “estimate”, “project”, “plan”, “may”, “should”, “would”, “will”, “intend”, “believe” and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.
- Contact Information
- Rianne Roukema
- Corporate Communications
- OctoPlus N.V.
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.